Literature DB >> 14545007

Biologically active secondary metabolites from myxobacteria.

H Reichenbach1, G Höfle.   

Abstract

New chemical structures with proven biological activity still are badly needed for a host of applications and are intensively screened for. Suitable compounds may be used as such, or in the form of their derivatives or, equally important, may serve as lead compounds for designing synthetic analogs. One way to new compounds is the exploitation of new producer organisms. During the past 15 years the myxobacteria have been shown in our laboratories to be a rich source of novel secondary metabolites, many of the compounds showing interesting and sometimes unique mechanisms of action. About 50 basic structures and nearly 300 structural variants have been elucidated, and almost all of them turned out to be new compounds. Several myxobacterial substances may have a good chance of an application.

Year:  1993        PMID: 14545007     DOI: 10.1016/0734-9750(93)90042-l

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  24 in total

1.  Quantitative Analysis of Lysobacter Predation.

Authors:  Ivana Seccareccia; Christian Kost; Markus Nett
Journal:  Appl Environ Microbiol       Date:  2015-07-31       Impact factor: 4.792

Review 2.  Development of antibiotics and the future of marine microorganisms to stem the tide of antibiotic resistance.

Authors:  Noer Kasanah; Mark T Hamann
Journal:  Curr Opin Investig Drugs       Date:  2004-08

3.  A method for the selective isolation of Myxococcus directly from soil.

Authors:  J P Karwowski; G N Sunga; S Kadam; J B McAlpine
Journal:  J Ind Microbiol       Date:  1996-04

Review 4.  Recent advances in the social and developmental biology of the myxobacteria.

Authors:  M Dworkin
Journal:  Microbiol Rev       Date:  1996-03

5.  Evolution of sensory complexity recorded in a myxobacterial genome.

Authors:  B S Goldman; W C Nierman; D Kaiser; S C Slater; A S Durkin; J A Eisen; J Eisen; C M Ronning; W B Barbazuk; M Blanchard; C Field; C Halling; G Hinkle; O Iartchuk; H S Kim; C Mackenzie; R Madupu; N Miller; A Shvartsbeyn; S A Sullivan; M Vaudin; R Wiegand; H B Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

6.  In vitro reconstitution of the myxochelin biosynthetic machinery of Stigmatella aurantiaca Sg a15: Biochemical characterization of a reductive release mechanism from nonribosomal peptide synthetases.

Authors:  N Gaitatzis; B Kunze; R Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

7.  Myxobacterium-produced antibiotic TA (myxovirescin) inhibits type II signal peptidase.

Authors:  Yao Xiao; Klaus Gerth; Rolf Müller; Daniel Wall
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

8.  Genome Analysis of the Fruiting Body-Forming Myxobacterium Chondromyces crocatus Reveals High Potential for Natural Product Biosynthesis.

Authors:  Nestor Zaburannyi; Boyke Bunk; Josef Maier; Jörg Overmann; Rolf Müller
Journal:  Appl Environ Microbiol       Date:  2016-01-15       Impact factor: 4.792

Review 9.  Discovery and development of the epothilones : a novel class of antineoplastic drugs.

Authors:  Hans Reichenbach; Gerhard Höfle
Journal:  Drugs R D       Date:  2008

10.  Ecological variables affecting predatory success in Myxococcus xanthus.

Authors:  Kristina L Hillesland; Richard E Lenski; Gregory J Velicer
Journal:  Microb Ecol       Date:  2007-04-05       Impact factor: 4.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.